Moleculin Biotech, Inc.

MBRXNASDAQ • USD
ThemeHealthcare - Oncology›Targeted Therapy & Precision Oncology
0.75 USD
↘ 0.02 (3.04%)AT CLOSE (11:59 AM EDT)
0.78
↗ 0.03 (3.51%)
POST MARKET (AS OF 07:56 PM EDT)
Post Market
AS OF 07:56 PM EDT
0.78
↗ 0.03 (3.51%)
🔴Market: CLOSED

MBRX is currently priced at $0.77. The technical outlook is "Sell" and the fundamental picture shows "Neutral". Notable factors include a concerning Altman Z-Score in the distress zone, a weak Piotroski F-Score of 0/9, negative Return on Equity and a bearish Death Cross on the long-term moving averages. The stock looks compelling on valuation, with multiples below sector averages across P/E, P/B, and EV/EBITDA.

Technical & fundamental data as of Sep 15, 2026.

Open?$0.81
High?$0.82
Low?$0.75
Prev. Close?$0.78
Volume?475.5K
Avg. Volume?935.9K
VWAP?$0.78
Rel. Volume?0.51x
Bid / Ask
Bid?$0.77 × 1.3K
Ask?$0.78 × 3.6K
Spread?$0.01
Midpoint?$0.77
Valuation & Ratios
Market Cap?14.6M
Shares Out?19.5M
Float?17.9M
Float %?92.1%
P/E Ratio?N/A
P/B Ratio?1.26
EPS?-$1.67
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
Moleculin Biotech Inc is a late-stage pharmaceutical development company currently evaluating Annamycin, also known as L-Annamycin and by its generic name naxtarubicin. The company has two additional portfolios of technologies for hard-to-treat cancers and viruses with clinical and preclinical research funded by investigators at academic institutions. The Company operates in one reportable segment, which is the development and commercialization of drug products.
Themes
Healthcare - Oncology›Targeted Therapy & Precision OncologyBiotech - Drug Development›Infectious Disease & Vaccines
Employees
17
Market Cap
15.1M
Industry
PHARMACEUTICAL PREPARATIONS
Website
www.moleculin.com
Listed
2016-06-02
Address
5300 MEMORIAL DRIVE
HOUSTON, TX 77007
Phone: 713-300-5160
Technical OutlookSell
Strong SellNeutralStrong Buy
Long-Term (Tide)?▼ Bearish(-2/3)
Medium-Term (Wave)?▼ Bearish(-1/3)
Short-Term (Ripple)?▼ Bearish(-1/3)
MA Alignment?Mixed
Full Technical Analysis →
Fundamental OutlookNeutral
Strong SellNeutralStrong Buy
F-Score?
3
Z-Score?
0
Momentum?
65
Short Sent.?
100
Piotroski F-Score?0/9Weak
Altman Z-Score?-18.67Distress
Confidence?43%Low
Full Fundamental Analysis →
Short InterestLow
Short % of Float?0.99%Low
Short Interest?178.1K
Days to Cover?1.0
Free Float17.9M
Avg Daily Volume691.1K
Settlement Date2026-08-31
Financial Health
Current Ratio?0.94Weak
Quick Ratio?0.94Weak
Cash Ratio?0.78Adequate
Debt/Equity?0.00Low
ValuationATTRACTIVELY VALUEDvs 1 peers + S&P 500
Score
100/100
P/E?
N/A▾
P/B?
Peers
100
S&P
92
1.26CHEAP▾
P/S?
N/A▾
P/FCF?
N/A▾
EV/EBITDA?
S&P
97
-0.3CHEAP▾
EV/Sales?
N/A▾
Returns & Efficiency
ROE?
S&P
3
-280.7%WEAK▾
ROA?
S&P
3
-154.2%WEAK▾
Cash Flow & Enterprise
FCF?$-25357000
Enterprise Value?$7.3M
Fundamentals ratios updated end of day
MarketsMoversWatchlist